Article

Absolute Configuration and Biological Evaluation of Novel Triterpenes as Possible Anti-Inflammatory or Anti-Tumor Agents

Zhenzhen Wei 1,2,,†, Tiqiang Zhou 1,2,3,,†, Ziming Xia 2, Sifan Liu 2, Min Li 2, Guangjie Zhang 2, Ying Tian 2, Bin Li 2, Lin Wang 2,* and Shuchen Liu 2,*

1 Faculty of Environment and Life, Beijing University of Technology, Beijing 100022, China
2 Department of Pharmaceutical Science, Beijing Institute of Radiation Medicine, Beijing 100850, China
3 School of Life Science, Beijing Institute of Technology, Beijing 100081, China
* Correspondence: biorm2022@163.com (L.W.); liusc118@163.com (S.L.)
† These authors contributed equally to this work.

Abstract: Two new compounds, ardisiapunine B (1) and ardisiapunine C (2), were isolated from Ardisia lindleyana D. Dietr. Their structures were examined using HR–ESI–MS, IR, (1D, 2D) NMR spectroscopic analyses, single–crystal X–ray diffraction, and ECD calculation. It was found that the two new compounds belong to unusual oleanane–type triterpenes, with compound 1 bearing an acetal unit and a C–13–C–18 double bond, and compound 2 bearing a C–28 aldehyde group and a C–18–C–19 double bond. The anti-inflammatory properties of compounds 1 and 2 were tested on NO production and cellular morphology using RAW264.7 cells, and their anti-tumor properties were tested on cytotoxic activities, cellular morphology, cell apoptosis, and cell cycle. The results showed that compound 1 exhibited a potent cytotoxicity against HepG2 cell lines with an IC
50 of 12.40 µM. Furthermore, it is possible that compound 1 inhibits cell proliferation by blocking the cell G2/M phase and promoting cell apoptosis. Compound 2 exhibited a potential anti-inflammatory activity by decreasing the production of NO in LPS–stimulated RAW264.7 cells. Comparative analysis of the structures of compounds 1 and 2 revealed that the acetal structure and double bond positions were the main differences between them, and these are presumed to be the main reasons for the extreme differences in their cytotoxicity and anti-inflammatory activities. From these new findings, two promising lead compounds were identified for the future development of potential anti–inflammatory or anti–tumor agents.

Keywords: Ardisia lindleyana D. Dietr; triterpene; ardisiapunine B; ardisiapunine C; absolute configurations; single–crystal X–ray diffraction; biological activity

1. Introduction

Ardisia lindleyana D. Dietr, a kind of evergreen dwarf shrub, belongs to the family of Myrsinaceae. It is mainly distributed across tropical America, the Pacific Islands, the eastern Indian Peninsula, Eastern Asia, and Southern Asia [1], and is grown for use in traditional Miao Minority medicine and as an ornamental shrub [2]. Previous research on the chemical constituents of this plant has led to the isolation of isocoumarins [3], quinones [4,5], and triterpenoids [3], some of which were found to have various bioactivities, including anti–inflammatory and anti–tumor activities.

In preliminary studies, we reported that the ethanol extract of the plant had a significant inhibitory effect on the proliferation of multiple tumor cells in vitro, disclosing that this plant may contain natural products with anti–tumor properties [6]. In this paper, we report the results of our further chemical investigation of Ardisia lindleyana D. Dietr, which led to the isolation of two new oleanane–type triterpenes, one with a diacetal moiety (1) and another with an aldehyde group (2). Their structures, including absolute configurations,
were characterized by one- and two-dimensional NMR spectroscopic analyses, including DEPT, HSQC, HMBC, $^1$H–$^1$H COSY, and NOESY experiments, single-crystal X-ray diffraction, and ECD calculation. Details of the structural elucidations for compounds 1 and 2 are shown in Figure 1A. The structures of the new compounds 1 and 2, both oleanane-type triterpenes, are novel, with compound 1 bearing an acetal unit and a C–13–C–18 double bond, and compound 2 bearing a C–28 aldehyde group and a C–18–C–19 double bond. The characterization of compounds 1 and 2 add not only to the diversity of the chemical constituents of Ardisia lindleyana D. Dietr, but also to the diversity of oleanane-type triterpenes.

![Chemical structures](image)

**Figure 1.** Chemical structures (A), key $^1$H–$^1$H COSY and HMBC correlations (B), and NOESY correlations (C) of compounds 1 and 2.

Triterpenes are common in nature and engage in various biological activities, such as anti-tumor activity, anti-inflammatory activity, antibacterial activity, and antiviral activity. Among these, the anti-tumor activity of triterpenes is measured by their ability to induce apoptosis, block nuclear factor–kappaB activation, inhibit signal transducer, inhibit topoisomerases, and activate transcription and angiogenesis [7]. Hence, compounds 1 and 2 were evaluated for their cytotoxicity against B16F10, A549, H460, MCF–7, HepG2, Hela, and U87 cell lines in vitro, and evaluated for their anti-inflammatory properties using the Griess reaction and the results of screening the production of NO by LPS–stimulated murine macrophage cell lines RAW264.7.

### 2. Results and Discussion

#### 2.1. Phytochemical Identification

Ardisiapunine B (1) was obtained as a white amorphous powder. The purity of compound 1 was more than 95% according to HPLC analysis. The IR spectrum showed absorption bands assignable to hydroxyl (3450 cm$^{-1}$), double bond (1644 cm$^{-1}$), alkyl (1460 cm$^{-1}$), and methyl (1387 cm$^{-1}$) functional groups. The HR-ESI-MS gave a molecular formula of C$_{31}$H$_{50}$O$_4$Na at $m/z$ 509.3598 [M + Na]$^+$ (calcd. for C$_{31}$H$_{50}$O$_4$Na$^+$, 509.3607) with 7 degrees of unsaturation. The $^{13}$C NMR spectrum of compound 1 showed 31 carbon signals (Table 1). Combined with the $^{13}$C NMR and DEPT (45, 90, 135) experiment, 31 carbon
signals were categorized as follows: 2 sp² olefinic carbons at δC 131.7 ppm and 134.1 ppm, 6 sp³ quaternary carbons at δC 38.9 ppm, 40.7 ppm, 40.9 ppm, 43.2 ppm, 45.7 ppm, and 45.8 ppm, 3 sp³ oxymethine carbons at δC 72.1 ppm, 79.3 ppm, and 109.7 ppm, 2 sp³ methine carbons at δC 52.8 ppm and 57.4 ppm, 1 oxymethylene carbon at δC 72.2 ppm, 10 sp³ methane carbons at δC 20.2 ppm, 23.5 ppm, 25.9 ppm, 27.1 ppm, 29.6 ppm, 32.6 ppm, 36.1 ppm, 36.9 ppm, 38.1 ppm, and 40.8 ppm, 1 oxymethyl carbons at δC 56.2 ppm, and 6 methyl carbons at δC 17.7 ppm, 18.3 ppm, 20.2 ppm, 27.4 ppm, 29.9 ppm, and 30.0 ppm. The ¹H NMR (Pyridine–d$_5$, 400 MHz) spectrum (Table 1) of compound 1 displayed six methyl singlets at δH 0.88 ppm (3H, s, H–25), 0.98 ppm (3H, s, H–29), 1.00 ppm (3H, s, H–26), 1.02 ppm (3H, s, H–24), 1.20 ppm (3H, s, H–23), and 1.40 ppm (3H, s, H–27), a methoxy signal at δH 3.40 ppm (3H, s, H–31), an oxymethine signal at δH 3.47 ppm (1H, t, J = 7.5 Hz, H–3), an oxymethylene signal at δH 3.82 ppm (1H, t, J = 4.0 Hz, H–28), and a methenedioxy group at δH 4.40 ppm (1H, s, H–30). Four spin coupling systems (H$_2$–2–H–3, H$_2$–11–H$_2$–12, H$_2$–15–H–16, and H$_2$–21–H$_2$–22) were revealed by the analysis of the ¹H–¹H COSY data for compound 1 (Figure 1B). Combined with the ¹H–¹H COSY data, the HMBC correlations (Figure 1B) from H–3 to C–1/C–2/C–23/C–24, from H–12 to C–11/C–9/C–13/C–14, from H–5 to C–10/C–18, from H–19 to C–13/C–18/C–20/C–21, from H–30 to C–19/C–28/C–29/C–31, from H–28 to C–18/C–22, and from H–16 to C–17 revealed the partial structure of compound 1. Based on the above observations, the molecular formula, the degree of unsaturation, and the chemical shift characteristics, the whole planar structure of compound 1 was assigned as shown in Figure 1A.

| NO | δC, Mult. | δH (J in Hz) | δC, Mult. | δH (J in Hz) | δC, Mult. | δH (J in Hz) | δC, Mult. | δH (J in Hz) |
|----|-----------|--------------|-----------|--------------|-----------|--------------|-----------|--------------|
| 1  | 40.8, CH₂ | overlapped   | 39.1, CH₂ | overlapped   | 39.3, CH₂ | overlapped   | 39.3, CH₂ | overlapped   |
| 2  | 29.6, CH₂ | overlapped   | 28.1, CH₂ | overlapped   | 28.1, CH₂ | overlapped   | 28.1, CH₂ | overlapped   |
| 3  | 79.3, CH  | 3.47, t (7.5)| 77.8, CH  | 3.42, m      | 77.8, CH  | 3.44, t (7.5)| 77.8, CH  | 3.44, t (7.5)|
| 4  | 40.9, C   |             | 39.3, C   |             | 39.3, C   |             | 39.3, C   |             |
| 5  | 57.4, CH  | overlapped   | 55.8, CH  | overlapped   | 55.7, CH  | overlapped   | 55.7, CH  | overlapped   |
| 6  | 20.2, CH₂ | overlapped   | 18.4, CH₂ | overlapped   | 18.4, CH₂ | overlapped   | 18.4, CH₂ | overlapped   |
| 7  | 36.1, CH₂ | overlapped   | 34.8, CH₂ | overlapped   | 34.7, CH₂ | overlapped   | 34.7, CH₂ | overlapped   |
| 8  | 43.2, C   |             | 42.4, C   |             | 42.4, C   |             | 42.4, C   |             |
| 9  | 52.8, CH  | overlapped   | 50.6, CH  | overlapped   | 50.7, CH  | overlapped   | 50.7, CH  | overlapped   |
| 10 | 38.9, C   |             | 37.2, C   |             | 37.2, C   |             | 37.2, C   |             |
| 11 | 23.5, CH₂ | overlapped   | 20.9, CH₂ | overlapped   | 21.1, CH₂ | overlapped   | 21.1, CH₂ | overlapped   |
| 12 | 27.1, CH₂ | 2.57, d (13.7), Ha overlapped, Hb | 26.1, CH₂ | overlapped, Ha overlapped, Hb | 26.2, CH₂ | overlapped, Ha overlapped, Hb | 26.2, CH₂ | overlapped, Ha overlapped, Hb |
| 13 | 134.1, C  |             | 40.7, CH  | 2.67, d (9.4) | 40.3, CH  |             | 2.71, d (9.6) |             |
| 14 | 45.7, C   |             | 40.8, C   |             | 40.7, C   |             | 40.7, C   |             |
| 15 | 38.1, CH₂ | overlapped   | 39.6, CH₂ | overlapped   | 39.5, CH₂ | overlapped   | 39.5, CH₂ | overlapped   |

**Table 1.** NMR data of compounds 1, 2, and 2-DNP in pyridine (400 MHz for ¹H; 100 MHz for ¹³C).
Table 1. Cont.

| NO  | δ_C, Mult. | δ_H (J in Hz) | δ_C, Mult. | δ_H (J in Hz) | δ_C, Mult. | δ_H (J in Hz) |
|-----|------------|----------------|------------|----------------|------------|----------------|
| 27  | 27.4, CH_3 | 1.40, s        | 16.0, CH_3 | 0.95, s        | 16.4, CH_3 | 1.00, s        |
| 28  | 72.2, CH_2 | overlapped, Ha | 205.9, CH  | 10.39, s       | 157.4, CH  | 8.65, s        |
| 29  | 29.9, CH_3 | 0.98, s        | 23.9, CH_3 | 1.24, s        | 23.9, CH_3 | 1.30, s        |
| 30  | 109.7, CH  | 4.40, s        | 71.5, CH_2 | 3.68, m        | 72.1, CH_2 | 3.68, dd (10.2, 25.2) |
| 31  | 56.2, CH_3 | 3.40, s        |            |                |            |                |
| 1'  |            |                |            |                |            |                |
| 2'  |            |                |            |                |            |                |
| 3'  |            |                |            |                |            |                |
| 4'  |            |                |            |                |            |                |
| 5'  |            |                |            |                |            |                |
| 6'  |            |                |            |                |            |                |

The relative stereochemistry of compound 1 was ascertained from the NOE interactions (Figure 1C) observed in the NOESY spectrum. Significant NOE correlations were observed between H–12 and H–19, H–19 and H–28, H–19 and H–30, H–28 and H–31, H–31 and H–30, and H–30 and H–21. These NOE interactions suggested that C–28, C–30, and C–31 were on the axial positions. The absolute configuration of compound 1 was further secured by a successful X-ray diffraction experiment (Flack parameter −0.004 (13)), which established the absolute configuration of compound 1 as 3S, 5R, 8R, 9R, 10R, 14S, 16R, 17S, 20S, and 30S (Figure 2). Thus, the structure of compound 1 was established and named ardisiapunine B.

Figure 2. X-ray structure of compound 1.

Ardisiapunine C (2) was obtained as a white amorphous powder. The purity of compound 2 was more than 95% according to HPLC analysis. The IR spectrum showed absorption bands assignable to hydroxyl (3379 cm⁻¹), methylene (2937 cm⁻¹), aldehyde (2868 cm⁻¹, 2723 cm⁻¹ and 1715 cm⁻¹), double bond (1650 cm⁻¹), alkyl (1451 cm⁻¹), and methyl (1384 cm⁻¹) functional groups. The HR-ESI-MS gave a protonated molecule peak of m/z 495.3448 [M + Na]⁺ (calcd. for C_{30}H_{48}O_{4}Na, 495.3450) and indicated the molecular formula of C_{30}H_{48}O_{4} (7 degrees of unsaturation). Thirty carbon signals were observed in the 13C NMR of compound 2 (Table 1). The DEPT spectra of compound 2 indicated the presence of two sp² olefinic carbons at δ_C 132.1 ppm and 137.4 ppm, one sp² aldehyde carbon at δ_C 205.9 ppm, two sp³ oxymethine carbons at δ_C 75.5 ppm and 77.8 ppm, one sp³ oxymethylene carbon at δ_C 71.5 ppm, six sp³ quaternary carbons, three sp³ methine carbons, nine sp³ methylene carbons, and six sp³ methyl carbons. The 1H NMR (Pyridine-d5, 400 MHz) spectrum of compound 2 (Table 1) showed six methyl singlets at δ_H 0.85 ppm
(3H, s, H–25), 0.95 ppm (3H, s, H–27), 1.01 ppm (3H, s, H–26), 1.07 ppm (3H, s, H–24), 1.19 ppm (3H, s, H–23), and 1.24 ppm (3H, s, H–29), three oxymethylene signals at δH 3.42 ppm (m, H–3), 3.68 ppm (m, H–30), and 4.12 ppm (dd, J = 4.56, 11.92 Hz, H–16), and one double bond signal at δH 5.65 ppm (s, H–19). Extensive 2D NMR experiments allowed us to define the molecular connectivity. The analysis of the 1H–1H COSY experiment and the coupling constant values of the protons revealed the presence of four isolated spin systems, as shown in Figure 1B. Combined with the 1H–1H COSY data, the HMBC correlations (Figure 1B) from H–3 to C–4/C–23/C–24, from H–13 to C–12/C–8, from H-15 to C–8/C–16/C–17, from H-16 to C–12/C–17/C–22/C–28, from H–22 to C–13/C–17/C–28, and from H–19 to C–17/C–21/C–29/C–30 revealed the partial structure of compound 2. Compound 2 is an oleanolane pentacyclic triterpene with ten chiral carbons. According to the basic chemical structure of 3–hydroxyl oleanane-type pentacyclic triterpenes (Figure 3C), the relative configurations of the nine chiral carbons in compound 2 were assigned as 3S*, 5R*, 8R*, 9R*, 10R*, 13S*, 14R*, 17R*, and 20S*. The observed NOESY correlations (Figure 1C) between H–13 and H–28, and H–16 and H–28 indicated that H–13, H–16, and H–28 were on the same axial orientation. Therefore, the relative configuration of C–16 in compound 2 was 16R*.

![Figure 3.](image-url)
Figure S32 in Supporting Information) gave a protonated molecule peak of \( m/z \) 651.3763 [\( \text{M} + \text{H} \)^−] (calcd. for \( \text{C}_{36}\text{H}_{31}\text{N}_{4}\text{O}_{7}\text{Na}^+ \), 651.3758) and indicated the molecular formula of \( \text{C}_{36}\text{H}_{32}\text{N}_{4}\text{O}_{7} \) (13 degrees of unsaturation). The structure of compound 2–DNP was confirmed using IR spectroscopy (Supplementary Figure S36 in Supporting Information), which showed absorption bands at 1616 cm\(^{-1}\) (C=N), 1132 cm\(^{-1}\) (C–N), and 1330 cm\(^{-1}\) (–NO\(_2\)). Additionally, the disappearance of a band at 1715 cm\(^{-1}\) was detected (C=O). The \( ^{13}\text{C} \) NMR spectrum of compound 2–DNP (Table 1) revealed the disappearance of carbon signals at 205.9 ppm (C=O), as well as the appearance of six peaks at \( \delta_C \) 116.7 ppm, 122.7 ppm (overlapped), 129.0 ppm, 129.6 ppm, 137.2 ppm, and 145.6 ppm, and three signals at \( \delta_C \) 8.12 ppm, 8.19 ppm, and 9.04 ppm in the \( ^1\text{H} \) NMR spectra (Table 1), which were attributed to a benzene group. Moreover, the presence of hydrazone moiety (C=N–H) was confirmed by the singlet peaks at 11.8 ppm and 157.4 ppm in the \( ^1\text{H} \) NMR and \( ^{13}\text{C} \) NMR spectra, respectively.

During the process of derivatization of compound 2 to compound 2–DNP, the chiral carbons of compound 2 were not directly involved in this derivative reaction. The relative configurations of (3S*, 5R*, 8R*, 9R*, 10R*, 13S*, 14R*, 16R*, 17S*, 20S*)–2–DNP were determined by ECD calculation. The calculated ECD curve of (3S, 5R, 8R, 9R, 10R, 13S, 14R, 16R, 17S, 20S)–2–DNP was similar to that obtained in the experiment (Figure 3B). Thus, the absolute configuration of compound 2 was established as 3S, 5R, 8R, 9R, 10R, 13S, 14R, 16R, 17R, and 20S, and named ardisiapunine C.

In this work, two new oleanane–type triterpenes were obtained from Ardisia lindleyana D. Dietr. This is the first report about oleanane–type triterpenes with double bonds at C–13–C–18 or C–18–C–19 obtained from Ardisia lindleyana D. Dietr, which has broadened our understanding of the structural diversity of this genre of metabolites. To the best of our knowledge, although an oleanane–type triterpene containing an acetal moiety had been reported [11], there are no reports of one with the properties of compound 1. This is the first report about oleanane–type triterpenes with double bonds at C–13–C–18 that have been obtained from natural sources. It is worth mentioning that such compounds, with a double bond at this position, are very special and rare. The structure of compound 2, bearing a C–28 aldehyde group and a C–18–C–19 double bond, also appears to be unique.

2.2. Structural Information of Compounds 1 and 2

Ardisiapunine B (1): White amorphous powder; UV (DMSO) \( \lambda_{\text{max}} \) 210 nm; HR–ESI–MS (positive) \( m/z \) 509.3598 [\( \text{M} + \text{Na} \)^+] (calcd. for \( \text{C}_{31}\text{H}_{30}\text{O}_{4}\text{Na}^+ \), 509.3607); IR (KBr) \( \nu_{\text{max}} \) 3450 cm\(^{-1}\), 2942 cm\(^{-1}\), 1644 cm\(^{-1}\), 1460 cm\(^{-1}\), 1378 cm\(^{-1}\), 1044 cm\(^{-1}\), and 974 cm\(^{-1}\); for \( ^1\text{H} \) and \( ^{13}\text{C} \) NMR see Table 1.

Ardisiapunine C (2): White amorphous powder; UV (MeOH) \( \lambda_{\text{max}} \) 210 nm; HR–ESI–MS (positive) \( m/z \) 495.3448 [\( \text{M} + \text{Na} \)^+] (calcd. for \( \text{C}_{30}\text{H}_{40}\text{O}_{4}\text{Na}^+ \), 495.3450); IR (KBr) \( \nu_{\text{max}} \) 3379 cm\(^{-1}\), 2937 cm\(^{-1}\), 2868 cm\(^{-1}\), 2723 cm\(^{-1}\), 1715 cm\(^{-1}\), 1650 cm\(^{-1}\), 1451 cm\(^{-1}\), 1384 cm\(^{-1}\), and 1036 cm\(^{-1}\); for \( ^1\text{H} \) and \( ^{13}\text{C} \) NMR see Table 1.

2.3. X-Ray Crystallographic Analysis of Compound 1

\( \text{C}_{31}\text{H}_{30}\text{O}_{4} \) (M = 486.37 g/mol): The empirical formula containing one molecule of chloroform was \( \text{C}_{32}\text{H}_{31}\text{Cl}_{13}\text{O}_{4} \) (M = 606.08 g/mol), orthorhombic, \( a = 7.2094(19) \) Å, \( b = 11.7688(3) \) Å, \( c = 37.0363(10) \) Å, \( U = 3142.38(15) \) Å\(^3\), \( T = 115.85(10) \), space group \( P2_12_12_1 \) (no. 19), \( Z = 4 \), \( \mu \) (Cu Ka) = 2.908, 10984 reflections measured, 5938 unique (Rint = 0.0324), which were used in all calculations. The final R1 (I > 2\( \sigma \)(I), i.e., \( F_O > 4\sigma (F_O) \)) was 0.0434, and the wR2 was 0.1161. The final wR (\( F^2 \)) was 0.1193 (all data). Flack parameter = −0.004(13).

Detailed parameters are shown in Table 2. The crystallographic data were deposited at the Cambridge Crystallographic Data Center with the deposition number CCDC 2119390. Copies of the data can be obtained, free of charge, on application to CCDC, 12 Union Road, Cambridge CB2 1EZ, U.K. (fax +44(0)-1233-336033; email: deposit@ccdc.cam.ac.uk).
Table 2. Crystal data and structure refinement of compound 1.

| Parameter | Data |
|-----------|------|
| Empirical formula | C$_{32}$H$_{51}$Cl$_3$O$_4$ |
| Formula weight | 606.08 |
| Temperature / K | 115.85(10) |
| Crystal system | orthorhombic |
| Space group | P2$_1$2$_1$2$_1$ |
| a / Å, b / Å, c / Å | 7.20942(19), 11.7688(3), 37.0363(10) |
| α/°, β/°, γ/° | 90.00, 90.00, 90.00 |
| Volume / Å$^3$ | 3142.38(15) |
| Z | 4 |
| ρcalc / mg mm$^{-3}$ | 1.281 |
| µ / mm$^{-1}$ | 2.908 |
| F(000) | 1304 |
| Crystal size / mm$^3$ | 0.34 × 0.33 × 0.13 |
| 2θ range for data collection | 7.88 to 142.04° |
| Index ranges | -7 ≤ h ≤ 8, -14 ≤ k ≤ 10, -44 ≤ l ≤ 32 |
| Reflections collected | 10984 |
| Independent reflections | 5938[R(int) = 0.0324 [inf-0.9Å]] |
| Data/restraints/parameters | 5938/3/37 |
| Goodness-of-fit on F$^2$ | 1.050 |
| Final R indexes (I > 2σ (I), i.e., F$_o$ > 4σ (F$_o$)) | R$_1$ = 0.0434, wR$_2$ = 0.1161 |
| Final R indexes (all data) | R$_1$ = 0.0461, wR$_2$ = 0.1193 |
| Largest diff. peak/hole / e Å$^{-3}$ | 0.497/−0.373 |
| Flack Parameters | −0.004(13) |
| Completeness | 0.9982 |

2.4. Anti-Tumor Activity against Seven Cancer Cell Lines

2.4.1. Cytotoxic Activities

The cytotoxic activities of compounds 1 and 2 against a mouse melanoma cell line (B16F10), a human lung cancer cell line (A549), a human large cell lung cancer cell line (H460), a human breast cancer cell line (MCF–7), a human hepatocellular carcinoma cell line (HepG2), a human cervical carcinoma cell line (Hela), and a human glioma cell line (U87) were assayed using CCK–8 with cisplatin as the positive control. The results showed that compound 1 exhibited potent cytotoxic activities against HepG2 and B16F10, with 50% inhibitory concentration (IC$_{50}$) values of 12.40 µM and 17.51 µM, respectively (Table 3). The IC$_{50}$ values for the different tumor cells were as follows: HepG2 < B16F10 < MCF–7 < Hela < U87 < A549 < H460. However, compound 2 did not exhibit any cytotoxic activities on any of the seven cell lines. Comparative analysis of the structures of compounds 1 and 2 revealed that the acetal structure and double bond positions were the main differences between them, and these are presumed to account for the differences in cytotoxic activities. In other words, we believe that a C–30 acetal unit and a C–13–C–18 double bond are essential features for producing cytotoxic activities.

Table 3. Cytotoxic activity of compounds 1 and 2 against seven tumour cell lines in vitro.

| Compound | IC$_{50}$ (µM) |
|----------|----------------|
| B16F10 $^a$ | A549 $^b$ | H460 $^c$ | MCF–7 $^d$ | HepG2 $^e$ | Hela $^f$ | U87 $^g$ |
| 1 | 17.51 ± 3.55 | 29.86 ± 4.26 | 33.09 ± 0.58 | 21.73 ± 2.71 | 12.40 ± 3.76 | 24.96 ± 6.88 | 25.50 ± 3.45 |
| 2 | >100 | >100 | >100 | >100 | >100 | >100 | >100 |
| cisplatin | 9.07 ± 0.66 | 8.45 ± 0.74 | 9.63 ± 0.49 | 8.23 ± 0.43 | 9.89 ± 0.61 | 8.26 ± 0.51 | 8.89 ± 0.63 |

Note: Data are presented as means ± SD, n = 3; ND, no detection; $^a$ mouse melanoma cell line (B16F10); $^b$ human lung cancer cell line (A549); $^c$ human large cell lung cancer cell line (H460); $^d$ human breast cancer cell line (MCF–7); $^e$ human hepatocellular carcinoma cell line (HepG2); $^f$ human cervical carcinoma cell line (Hela); $^g$ human glioma cell line (U87).
2.4.2. Cell Morphology

To assess whether compound 1 could induce any morphological changes, HepG2 cells were incubated with different concentrations of compound 1. The cells were then observed and photographed using a fluorescence microscope after being stained with 3,3′-dioctadecyloxacarbocyanine perchlorate (Dio) and Hoechst 33342 [12,13]. As shown in Figure 4A, compound 1 altered the cellular morphology considerably regardless of the dose. The untreated HepG2 cells (control group) exhibited a regular appearance, intensive growth, integral cell membrane, and clear nucleolus. After treatment with compound 1, cell membrane and nuclear condensation can be observed, and the cells were eventually destroyed, showing elongated or irregular shapes, condensation of chromatin, and cell shrinkage, which revealed that compound 1 could induce apoptosis in vitro.

2.4.3. Cell Apoptosis and Cell Cycle

In order to further explore the mechanism of compound 1 against tumors, HepG2 cells were incubated with different concentrations of compound 1 to observe its effect on cell apoptosis and cell cycle. The results showed that compound 1 could increase the cells in the G2/M phase from 17.53% to 22.05% (3.13 µM), 26.03% (6.25 µM), and 36.48% (12.5 µM) (Figure 4B,C), and the apoptosis rate from 14.31% to 24.00% (3.13 µM), 30.06% (6.25 µM), and 54.27% (12.5 µM) (Figure 4D,E) in a dose-dependent manner. Compared with the control group, compound 1 at concentrations of 6.25 µM and 12.5 µM significantly increased both the cells in the G2/M phase and the apoptosis rate (p < 0.01 or p < 0.001). Therefore, we speculated that compound 1 might inhibit cell proliferation by blocking the cell G2/M phase and promoting cell apoptosis.

2.5. Anti-Inflammatory Activity against NO Production

The anti-inflammatory assays of compounds 1 and 2 were evaluated in LPS–stimulated RAW264.7 macrophages with dexamethasone as the positive control. The results showed that compound 1 produced a cytotoxic effect on RAW264.7 cells. Therefore, the anti-inflammatory activity of compound 1 has not been tested. The results also showed that compound 2 did not affect cell viability on RAW264.7 cells at a concentration of 50 µM to 6.25 µM (Figure 5B). As shown in Figure 5C, the results showed that compound 2 exhibited good inhibitory activity against NO production in a dose-dependent manner. In addition, we used a microscope to observe the effect of compound 2 on the cell morphology of LPS–stimulated RAW264.7 cells in order to more accurately evaluate its anti-inflammatory properties. As can be seen in Figure 5A, the cells in the control group were plump and round, but the cells undergoing LPS stimulation became flat and irregular, with slender tentacles. However, the LPS–stimulated cell morphology returned to normal when compound 2 intervened. The above results demonstrate that compound 2 exhibits a potential anti-inflammatory activity by decreasing the production of NO in LPS–stimulated RAW264.7 cells.
Figure 4. Effects of compound 1 on cell morphology, cell apoptosis, and cell cycle of HepG2 Cells in vitro. HepG2 cells were seeded in 12-well plates. After 24 h incubation, cells were incubated with compound 1 for another 48 h. Cell morphology assay (A): The cells were washed with PBS, fixed by paraformaldehyde, washed with PBS, stained with Dio, washed with PBS, stained with Hoechst 33342, and washed with PBS. The cells were then observed and photographed using a fluorescence microscope. Cell apoptosis (B,C) and cycle (D,E) assay: In the cell apoptosis assay, all the cells were collected, and 100,000 cells were taken and incubated with Annexin V–FITC and PI for 20 min at room temperature without light. In the cell cycle assay, all the cells were collected and fixed with precooled 70% ethanol for 12 h at 4 °C. The cells were then washed with PBS and incubated with PI for 30 min at 37 °C without light. Finally, all the cells were detected using a flow cytometer. Data are presented as mean ± SD, n = 3. One way ANOVA, ** p < 0.001, *** p < 0.001, compared with control group.
Figure 5. Effects of compound 2 on morphology (A), cell viability (B), and nitric oxide (NO) production (C) of LPS–stimulated RAW264.7 cells in vitro. After 24 h incubation, LPS–stimulated RAW264.7 cells were co-treated with LPS (1 µg/mL) and various concentrations of compound 2 for another 24 h. Dexamethasone was used as a positive control. In the cell morphology assay, the cells were observed and photographed using a microscope. Cell viability was determined using the CCK–8 method by measuring the absorbance with a microplate photometer at 450 nm. In (B,C), the abscissa groups from left to right are the control group (without LPS), model group, compound 1 at a concentration of 6.25 µM group, compound 1 at a concentration of 25 µM group, compound 1 at a concentration of 50 µM group and positive control group, respectively. In the NO production assay, the supernatants were collected for the measurement of NO production using the Griess reagent. Data are presented as mean ± SD, n = 3. One way ANOVA, *** p < 0.001, compared with LPS group.

3. Material and Methods

3.1. General Experimental Procedures

Silica gel (200–300 and 400–600 mesh, Qingdao Marine Chemical Co., Qingdao, China) and Sephadex LH–20 (Pharmacia Co., Stockholm, Sweden) were used for column chromatography (CC) and thin-layer chromatography (TLC). Analytical HPLC was performed on a Surveyor high performance liquid chromatography system (Thermo Fisher Co., Waltham, MA, USA) with an Alltech 2000ES evaporative light scattering detector (Alltech Co., Nicholasville, KY, USA). Preparative HPLC (Rp–C18: 21.2 × 150 mm, 5 µm, Innova C18, Agela Technologies Co. Ltd., Tianjin, China) was carried out on a KNAUER apparatus with a refractive index detector (Knauer Co., Berlin, Germany). IR data were recorded on a Bruker Tensor–27 spectrometer (Bruker Co., Billerica, MA, USA). High–resolution electrospray ionization mass spectrometry (HR-ESI-MS) was performed on the Agilent G6230A TOF LC/MS (Agilent Technologies Co. Ltd., Santa Clara, CA, USA). Both 1D and 2D NMR spectra were recorded on a Bruker ECA–400 MHz spectrometer (Bruker Co., Billerica, MA, USA) with TMS as an internal standard, and chemical shifts are expressed in d (ppm). ECD spectra were recorded in methanol using a JASCO J–815 spectrophotometer (Jasco International Co., Ltd., Tokyo, Japan) at room temperature.
3.2. Plant Materials

The roots of *Ardisia lindleyana* D. Dietr were collected from Guangxi (104°26′–112°04′ E, 20°54′–26°24′ N at an altitude of about 300 m) in China, and identified by Prof. Bin Li, Beijing Institute of Radiation Medicine. A voucher specimen (Voucher # 2018–0808) was deposited in the specimen cabinet of the Beijing Institute of Radiation Medicine.

3.3. Isolations of Compounds

The root bark (60 kg) was extracted with 80% EtOH. Upon concentration with a rotary evaporator, the root bark yielded a dark, brownish black residue (11.8 kg). This residue was then dispersed in deionized water and partitioned successively with petroleum ether, EtOAc, and n–BuOH. The EtOAc extract (290 g) was subjected to a silica gel column using Dichloromethane–MeOH (200–300 mesh, 100:0, 100:1, 50:1, 25:1, 10:1, 5:1, 2:1, and 1:1, v/v) to produce 12 fractions (Fr.1–Fr.12). Fr.2 (8.5 g) was fractionated and subjected to a silica gel column (200–300 mesh, Petroleum ether–ethyl acetate, 100:0, 100:1, 50:1, 25:1, 10:1, 5:1, 2:1, and 1:1, v/v) to produce 15 fractions (Fr.2–a–Fr.2–o). Fr.2–d (1.5 g) was further separated by preparative HPLC using MeOH–H₂O (85:15) to yield compound 1 (52.8 mg), and Fr.2–e (0.8 g) was further separated by preparative HPLC using MeOH–H₂O (65:35, v/v) to yield compound 2 (35.6 mg).

3.4. Effect of Isolated Compounds on Cytotoxicity of Seven Cancer Cell Lines

Seven cancer cell lines, the B16F10, A549, H460, MCF–7, HepG2, Hela, and U87 cancer cell lines, were utilized in the cytotoxic activities assay. The MCF–7, HepG2, Hela, and U87 cell lines were cultured in Dulbecco’s modified Eagle’s medium (DMEM, Gibco, Grand Island, NY, USA), and The B16F10, A549, and H460 cell lines were cultured in RPMI 1640 medium (RPMI 1640, SIGMA, U.S.), in each case supplemented with 10% fetal calf serum (Gibco, Grand Island, NY, USA), 100 U/mL penicillin, and 100 µg/mL streptomycin in an atmosphere containing 5% CO₂ at 37 °C. Cells were seeded in 96–well plates with a density of 5 × 10⁴ cells/mL and treated with different concentrations of the test compounds for 48 h. The cytotoxicity assay was performed using the Cell Counting Kit–8 (CCK–8, Applygen technologies Co., Ltd., Beijing, China) assay.

3.5. Effect of Compound 1 on Cell Morphology, Cell Cycle, and Apoptosis of HepG2 Cells

HepG2 cells were dispensed in a 12-well plate at a density of 5 × 10⁴ cells/mL, incubated at 37 °C for 24 h, and treated with different concentrations of compound 1 for 48 h.

3.5.1. Cell Morphology Assay

After removing the supernatant, the cells were washed twice with 1.0 mL PBS and fixed with 4% Paraformaldehyde fix solution (Shanghai Biyuntian Biotechnology Co., Ltd., Shanghai, China) for 2 h. Fixed cells were then washed twice with 1.0 mL PBS and incubated with Dio (Shanghai Biyuntian Biotechnology Co., Ltd., Shanghai, China) at 37 °C in darkness. After 20 min of incubation, the cells were washed twice with 1.0 mL PBS. Then, the cells were stained with Hoechst 33342 staining solution (Shanghai Biyuntian Biotechnology Co., Ltd., Shanghai, China) for 10 min and washed twice with 1.0 mL PBS. The stained cells in PBS were then observed and photographed using a fluorescence microscope.

3.5.2. Cell Apoptosis and Cell Cycle Assay

In the cell apoptosis assay, all the cells were collected, and 100,000 cells were taken and incubated with Annexin V–FITC and PI for 20 min at room temperature without light. In the cell cycle assay, all the cells were collected and fixed with precooled 70% ethanol for 12 h at 4 °C. The cells were then washed with PBS and incubated with PI for 30 min at 37 °C without light. All the cells were detected using a flow cytometer.
3.6. Effect of Isolated Compounds on NO Production

A RAW264.7 murine macrophage cell line (American Type Culture Collection, ATCC No. TIB-71) was purchased from the Cancer Institute and Hospital of the Chinese Academy of Medical Sciences. Cells were cultured in DMEM medium (Gibco, Grand Island, NY, USA) supplemented with 10% heat-inactivated fetal calf serum (Gibco, Grand Island, NY, USA), 100 U/mL penicillin, and 100 µg/mL streptomycin in an atmosphere containing 5% CO₂ at 37 °C. The cells were cultured for 3–5 days to reach the logarithmic phase and then used for experiments. The cells were treated with tested compounds and a positive control (dexamethasone) at different concentrations and then stimulated with LPS (1 µg/mL) for 24 h.

3.6.1. Cell viability Assay on RAW264.7 Cells

The cytotoxic effects of compounds 1 and 2 on RAW264.7 cells were evaluated using a CCK–8 assay. RAW264.7 cells were dispensed in a 96–well plate at a density of 1 × 10⁵ cell per well, incubated at 37 °C for 24 h, and treated with the tested agents for the indicated periods of time. Then, 10 µL of cell counting kit–8 solution was added to each well, followed by 1 h incubation. The absorbance at 450 nm of each well was measured with a Multiskan MK-3 microplate reader (Thermo Fisher Co., Waltham, MA, USA). Compound 2 showed no cytotoxic effect on RAW264.7 cells at different concentrations (6.25, 25, 50 µM). In addition, cell morphology was observed under an OLYMPUS CKX53 microscope (Olympus Co., Tokyo, Japan).

3.6.2. Determination of the NO Content

NO production was determined using a nitric oxide assay Kit (Applygen technologies Co., Ltd., Beijing, China) based on the Griess reaction principle [14,15]. A quantity of 50 microliters of culture supernatant was transferred to 96–well plates and mixed with 50 microliters of Griess R1 reagent after incubation at room temperature for 5 min. The samples were then mixed with an equal volume Griess R2 reagent for another 5 min. The absorbance of each mixture at 540 nm was measured using a microplate reader [16].

3.6.3. Cell Morphology Assay

Without any post-processing, the cells were observed and photographed using a microscope.

4. Conclusions

In this study, we identified two new compounds, including ardisiapunine B (1) and ardisiapunine C (2), which we isolated from Ardisia lindleyana D. Dietr. The structures of the two new compounds were elucidated using 1D and 2D NMR spectroscopic analyses, HR-ESI-MS, single-crystal X-ray diffraction, and ECD calculation. It was found that the two new compounds are unusual oleanane-type triterpenes, with compound 1 bearing an acetal unit and a C–13–C–18 double bond, and compound 2 bearing a C–28 aldehyde group and a C–18–C–19 double bond. Activity assay results showed that compound 1 exhibited a potent cytotoxicity against HepG2 and B16F10 cell lines, and that, furthermore, it might inhibit cell proliferation by blocking the cell G2/M phase and promoting cell apoptosis. These new findings provide a framework for the further exploration of compound 1, which exhibits potential anti-tumor activity by inducing cell cycle arrest and apoptosis. Compound 2 had moderate inhibitory effects on the production of NO in LPS-stimulated RAW264.7 cells. Comparative analysis of the structures of compounds 1 and 2 revealed that the acetal structure and different double bond positions were the main differences between them, and these are presumed to be the main reasons for the extreme differences in their cytotoxicity and anti-inflammatory activities. From these new findings, two promising lead compounds were identified for the future development of potential anti-inflammatory or anti-tumor agents.
Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/molecules27196641/s1, Figure S1: $^1$H NMR spectrum of 1. Figure S2: $^{13}$C NMR spectrum of 1. Figure S3: DEPT spectrum of 1. Figure S4: HSQC spectrum of 1. Figure S5: HMBC spectrum of 1. Figure S6: $^1$H-$^1$H COSY spectrum of 1. Figure S7: NOESY spectrum of 1. Figure S8: HR-ESI-MS spectrum of 1. Figure S9: HPLC–UV chromatogram of 1. Figure S10: HPLC–ELSD chromatogram of 1. Figure S11: Ultraviolet full wavelength scanning spectrum of 1. Figure S12: IR spectrum of 1. Figure S13: $^1$H NMR spectrum of 2. Figure S14: $^{13}$C NMR spectrum of 2. Figure S15: DEPT spectrum of 2. Figure S16: HSQC spectrum of 2. Figure S17: HMBC spectrum of 2. Figure S18: $^1$H–$^1$H COSY spectrum of 2. Figure S19: NOESY spectrum of 2. Figure S20: HR–ESI–MS spectrum of 2. Figure S21: HPLC–UV chromatogram of 2. Figure S22: HPLC–ELSD chromatogram of 2. Figure S23: Ultraviolet full wavelength scanning spectrum of 2. Figure S24: IR spectrum of 2. Figure S25: $^1$H NMR spectrum of 2–DNP. Figure S26: $^{13}$C NMR spectrum of 2–DNP. Figure S27: DEPT spectrum of 2–DNP. Figure S28: HSQC spectrum of 2–DNP. Figure S29: HMBC spectrum of 2–DNP. Figure S30: $^1$H–$^1$H COSY spectrum of 2–DNP. Figure S31: NOESY spectrum of 2–DNP. Figure S32: HR–ESI–MS spectrum of 2–DNP. Figure S33: HPLC–UV chromatogram of 2–DNP. Figure S34: HPLC–ELSD chromatogram of 2–DNP. Figure S35: Ultraviolet full wavelength scanning spectrum of 2–DNP. Figure S36: IR spectrum of 2–DNP.

Author Contributions: Conceptualization, L.W. and S.L. (Shuchen Liu); methodology, Z.W. and T.Z.; validation, B.L.; investigation, Z.X. and S.L. (Sifan Liu and); resources, G.Z. and M.L.; data curation, Y.T.; writing—original draft preparation, Z.W. and T.Z.; writing—review and editing, B.L., Y.T., L.W., and S.L. (Shuchen Liu); All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Data Availability Statement: The data presented in this study are available in the Supplementary Materials.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Kobayashi, H.; De Mejia, E. The genus Ardisia: A novel source of health-promoting compounds and phytopharmaceuticals. J. Ethnopharmacol. 2005, 3, 47–354. [CrossRef] [PubMed]
2. Li, C.; Yue, D.K.; Bu, P.B.; Sun, Y.F. Chemical constituents from roots of Ardisia punctata. China J. Chin. Mater. Med. 2006, 7, 562–565.
3. Ma, C.F.; Luo, M.; Lin, L.M.; Li, C.; Wang, Z.M.; Cheng, Y.Y. Chemical constituents of Ardisia punctata. China J. Chin. Mater. Med. 2012, 22, 3422–3425.
4. Li, C.; Yue, D.K.; Bu, P.B.; Sun, Y.F. Three new belamcandacauquinones from Ardisia punctata. Yao Xue Xue Bao 2006, 9, 830–834.
5. Li, C.; Yue, D.K.; Bu, P.B.; Sun, Y.F. Two novel compounds from Ardisia punctata Lindl. Yao Xue Xue Bao 2007, 9, 959–963.
6. De Mejia, E.G.; Ramírez-Mares, M.V. Ardisia: Health-promoting properties and toxicity of phytochemicals and extracts. Toxicol. Mech. Methods 2011, 9, 667–674. [CrossRef] [PubMed]
7. D’Yakonov, V.A.; Dzhemileva, L.U.; Dzhemilev, U.M. Advances in the Chemistry of Natural and Semisynthetic Topoisomerase I/II Inhibitors. Stud. Nat. Prod. Chem. 2017, 54, 21–86.
8. Superchi, S.; Scafato, P.; Gorecki, M.; Pescitelli, G. Absolute Configuration Determination by Quantum Mechanical Calculation of Chiroptical Spectra: Basics and Applications to Fungal Metabolites. Curr. Med. Chem. 2018, 2, 287–320. [CrossRef] [PubMed]
9. Pescitelli, G.; Di Bari, L.; Berova, N. Conformational aspects in the studies of organic compounds by electronic circular dichroism. Chem. Soc. Rev. 2011, 9, 4603–4625. [CrossRef] [PubMed]
10. Uchiyama, S.; Inaba, Y.; Kunugita, N. Derivatization of carbonyl compounds with 2, 4-dinitrophenylhydrazine and their subsequent determination by high-performance liquid chromatography. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2011, 17–18, 1282–1289. [CrossRef] [PubMed]
11. Liu, D.L.; Zhang, X.; Zhao, Y.M.; Wang, N.L.; Yao, X.S. Three new triterpenoid saponins from the roots of Ardisia crenata and their cytotoxic activities. Nat. Prod. Res. 2016, 23, 2694–2703. [CrossRef] [PubMed]
12. Chang, S.; Ruan, W.C.; Xu, Y.Z.; Wang, Y.F.; Fang, J.; Zhang, L.Y.; Liao, H.; Pang, T. The natural product 4,10-aromadendranediol induces neuritogenesis in neuronal cells in vitro through activation of the ERK pathway. Acta Pharmacol. Sin. 2007, 1, 29–40.
13. Wu, S.; Romero-Ramirez, L.; Mey, J. Retinoic acid increases phagocytosis of myelin by macrophages. J. Cell. Physiol. 2021, 5, 3929–3945. [CrossRef] [PubMed]
14. Ji, Y.S.; Sun, X.M.; Liu, X.Y.; Suo, X. Toxoplasma gondii: Effects of exogenous nitric oxide on egress of tachyzoites from infected macrophages. Exp. Parasitol. 2013, 1, 70–74. [CrossRef] [PubMed]
15. Kolodziej, H.; Radtke, O.A.; Kiderlen, A.F. Stimulus (polyphenol, IFN-gamma, LPS)-dependent nitric oxide production and antileishmanial effects in RAW264.7 macrophages. *Phytochemistry* 2008, 18, 3103–3110. [CrossRef] [PubMed]

16. Hong, Q.; Qi, K.; Feng, Z.; Huang, Z.Y.; Cui, S.Y.; Wang, L.Y.; Fu, B.; Ding, R.; Yang, J.R.; Chen, X.M.; et al. Hyperuricemia induces endothelial dysfunction via mitochondrial Na\(^+\)/Ca\(^{2+}\) exchanger-mediated mitochondrial calcium overload. *Cell Calcium* 2012, 5, 402–410. [CrossRef] [PubMed]